BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19355861)

  • 1. Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs?
    Boumendjel A; Ronot X; Boutonnat J
    Curr Drug Targets; 2009 Apr; 10(4):363-71. PubMed ID: 19355861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chalcones against the hallmarks of cancer: a mini-review.
    de Souza PS; Bibá GCC; Melo EDDN; Muzitano MF
    Nat Prod Res; 2022 Sep; 36(18):4809-4826. PubMed ID: 34865580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chalcone Derivatives: Role in Anticancer Therapy.
    Ouyang Y; Li J; Chen X; Fu X; Sun S; Wu Q
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer.
    WalyEldeen AA; Sabet S; El-Shorbagy HM; Abdelhamid IA; Ibrahim SA
    Chem Biol Interact; 2023 Jan; 369():110297. PubMed ID: 36496109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chalcones in cancer: understanding their role in terms of QSAR.
    Katsori AM; Hadjipavlou-Litina D
    Curr Med Chem; 2009; 16(9):1062-81. PubMed ID: 19275612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in chalcones with anticancer activities.
    Karthikeyan C; Moorthy NS; Ramasamy S; Vanam U; Manivannan E; Karunagaran D; Trivedi P
    Recent Pat Anticancer Drug Discov; 2015; 10(1):97-115. PubMed ID: 25138130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer.
    Rodrigues J; Abramjuk C; Vásquez L; Gamboa N; Domínguez J; Nitzsche B; Höpfner M; Georgieva R; Bäumler H; Stephan C; Jung K; Lein M; Rabien A
    Pharm Res; 2011 Apr; 28(4):907-19. PubMed ID: 21184149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural Chalcones and Their Derivatives Target the Tumor Microenvironment in Colon Cancer.
    Malla RR; Siragam S; Dadi V; Seetini B
    Crit Rev Immunol; 2022; 42(6):27-39. PubMed ID: 37082949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Cytotoxic Activities of Difluoro-Dimethoxy Chalcones.
    Yamali C; Gul HI; Ozgun DO; Sakagam H; Umemura N; Kazaz C; Gul M
    Anticancer Agents Med Chem; 2017; 17(10):1426-1433. PubMed ID: 28356013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methoxy- and fluoro-chalcone derivatives arrest cell cycle progression and induce apoptosis in human melanoma cell A375.
    Henmi K; Hiwatashi Y; Hikita E; Toyama N; Hirano T
    Biol Pharm Bull; 2009 Jun; 32(6):1109-13. PubMed ID: 19483325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.
    Boumendjel A; Boccard J; Carrupt PA; Nicolle E; Blanc M; Geze A; Choisnard L; Wouessidjewe D; Matera EL; Dumontet C
    J Med Chem; 2008 Apr; 51(7):2307-10. PubMed ID: 18293907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chalcones in cancer: understanding their role in terms of QSAR. II part.
    Repanas A; Katsori AM; Hadjipavlou-Litina D
    Mini Rev Med Chem; 2013 Jun; 13(7):952-70. PubMed ID: 22876949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of structure-activity relationship on plant polyphenol-induced suppression of human liver cancer cells.
    Loa J; Chow P; Zhang K
    Cancer Chemother Pharmacol; 2009 May; 63(6):1007-16. PubMed ID: 18766342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the antineoplastic potential of chalcones in animal models.
    Roman BI; Heugebaert TS; Bracke ME; Stevens CV
    Curr Med Chem; 2013; 20(2):186-221. PubMed ID: 23244582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chalcone Derivatives and their Activities against Drug-resistant Cancers: An Overview.
    Xiao J; Gao M; Diao Q; Gao F
    Curr Top Med Chem; 2021; 21(5):348-362. PubMed ID: 33092509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of synthesized 2'-oxygenated chalcone derivatives: modulation of human cell cycle phase distribution.
    Rao YK; Fang SH; Tzeng YM
    Bioorg Med Chem; 2004 May; 12(10):2679-86. PubMed ID: 15110849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight.
    Elkhalifa D; Alali F; Al Moustafa AE; Khalil A
    J Drug Target; 2019 Sep; 27(8):830-838. PubMed ID: 30582377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterocyclic chalcone analogues as potential anticancer agents.
    Sharma V; Kumar V; Kumar P
    Anticancer Agents Med Chem; 2013 Mar; 13(3):422-32. PubMed ID: 22721390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel synthetic chalcones induce apoptosis in the A549 non-small cell lung cancer cells harboring a KRAS mutation.
    Wang Y; Hedblom A; Koerner SK; Li M; Jernigan FE; Wegiel B; Sun L
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5703-5706. PubMed ID: 27810244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases.
    Shin SY; Yoon H; Hwang D; Ahn S; Kim DW; Koh D; Lee YH; Lim Y
    Bioorg Med Chem; 2013 Nov; 21(22):7018-24. PubMed ID: 24095020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.